About us

Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is high. A phase Ib/II study is now being conducted with a new dosing regimen that are expected to optimize the effect of the drug candidate.

Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

Colorectal cancer (CRC) Colorectal cancer is the third most common form of cancer globally after lung- and breast cancer and the second most deadly. Despite several medical advances in cancer research, the mortality rate for metastatic colorectal cancer remains high – 86 percent of patients with disseminated disease die within five years. Read more about colorectal cancer >>

Last updated 04-11-2025